3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase NA
1
Phase EARLY_PHASE1
1
Phase 4
1
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
24
Neoplasm Metastasis
8
Leukemia, Myeloid, Acute
8
Carcinoma, Renal Cell
7
Ovarian Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Colorectal Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Neuroblastoma
4
Neoplasms
4
Lymphoma
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Mesothelioma, Malignant
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Interventions
pembrolizumab
3
fludarabine
3
Cyclophosphamide
3
Ipilimumab
2
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
sargramostim
1
reolysin
1
poly ICLC
1
peginterferon alfa-2a
1
osimertinib
1
gusacitinib
1
fludarabine phosphate
1
eprenetapopt
1
epacadostat
1
dabrafenib
1
cobimetinib
1
cemiplimab
1
Vorinostat
1
Temozolomide
1
Radiotherapy
1
Radiation
1
Poly I-C
1
Nivolumab
1
Monatide (IMS 3015)
1
Methods
1
MAPRE1 protein, human
1
Interleukin-2
1
Interleukin-15
1
Interleukin-12
1
IT-101
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Skin Neoplasms
×
Interleukin-2
×
Clear all
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled